Michaelis E K, Magruder C D, Lampe R A, Galton N, Chang H H, Michaelis M L
Neurochem Res. 1984 Jan;9(1):29-44. doi: 10.1007/BF00967657.
Four amphipathic molecules with known local anesthetic activity, dibucaine, tetracaine, chlorpomazine, and quinacrine, inhibited the binding of L-[3H]glutamic acid to rat brain synaptic plasma membranes and to the purified glutamate binding protein. Neither haloperidol nor diphenylhydantoin had significant inhibitory effects on the glutamate binding activity of the membranes or of the purified protein. The amphipathic drugs apparently inhibited L-[3H]glutamate binding to synaptic membranes by a mixed type of inhibition. The inhibitory activity of quinacrine on glutamate binding to the synaptic membranes was greater in a low ionic strength, Ca2+-free buffer medium, than in a physiologic medium (Krebs-Henseleit buffer). Removal of Ca2+ from the Krebs solution enhanced quinacrine's inhibition of glutamate binding. Quinacrine up to 1 mM concentration did not inhibit the high affinity Na+-dependent L-glutamate transport in these membrane preparations. The importance of Ca2+ in the expression of quinacrine's effects on the glutamate binding activity of synaptic membranes and the observed tetracaine and chlorpromazine-induced increases in the transition temperature for the glutamate binding process of these membranes, were indicative of an interaction of the local anesthetics with the lipid environment of the glutamate binding sites.
四种具有已知局部麻醉活性的两亲性分子,丁卡因、丁哌卡因、氯丙嗪和奎纳克林,抑制L-[3H]谷氨酸与大鼠脑突触质膜以及纯化的谷氨酸结合蛋白的结合。氟哌啶醇和苯妥英对膜或纯化蛋白的谷氨酸结合活性均无显著抑制作用。两亲性药物显然通过混合型抑制作用抑制L-[3H]谷氨酸与突触膜的结合。在低离子强度、无Ca2+的缓冲介质中,奎纳克林对谷氨酸与突触膜结合的抑制活性比对生理介质(Krebs-Henseleit缓冲液)中的抑制活性更强。从Krebs溶液中去除Ca2+可增强奎纳克林对谷氨酸结合的抑制作用。浓度高达1 mM的奎纳克林在这些膜制剂中不抑制高亲和力的Na+依赖性L-谷氨酸转运。Ca2+在奎纳克林对突触膜谷氨酸结合活性的作用表达中的重要性,以及观察到的丁卡因和氯丙嗪诱导的这些膜谷氨酸结合过程转变温度的升高,表明局部麻醉药与谷氨酸结合位点的脂质环境存在相互作用。